• James R. Kasinger, general counsel and secretary, exercised stock options for 1,990 common shares at $13.62 on Oct. 6, 2026.
• He sold 1,990 common shares at a weighted average price of $60.0408 on the same day.
• Directly held common shares fell to 94,784 from 96,774.
• Directly held stock options declined to 81,242 following the exercise.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CRISPR Therapeutics AG published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-418101), on October 08, 2026, and is solely responsible for the information contained therein.